AstraZeneca Plc (LON:AZN), and its global biologics research and development arm MedImmune, announced today a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating..

AstraZeneca Plc (LON:AZN) and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced today detailed results from the Phase III SOLO-1 trial..

AstraZeneca Plc (LON:AZN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for..

AstraZeneca Plc (LON:AZN) and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by..

AstraZeneca Plc (LON:AZN) completed an agreement with Cheplapharm Arzneimittel GmbH (Cheplapharm) for the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in..

AstraZeneca Plc (LON:AZN) announced today positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT2 inhibitor CVOT conducted to date. The..

AstraZeneca Plc (LON:AZN) and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment..

AstraZeneca Plc (LON:AZN) and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma,..

AstraZeneca PLC (LON:AZN) announced the following Board and Board Committee appointments. New Non-Executive Director With effect from 1 October 2018, Joseph G. Peter (Joe) is appointed as a Non-Executive Director..

AstraZeneca PLC (LON:AZN) and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency has granted orphan designation..

AstraZeneca PLC (LON:AZN) and MedImmune, its global biologics research and development arm, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has..

AstraZeneca PLC (LON:AZN) has agreed to sell the commercial rights to Atacand and Atacand Plus in Europe to Cheplapharm Arzneimittel GmbH. Atacand is a prescription medicine for the treatment of..

AstraZeneca PLC (LON:AZN) and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after..

AstraZeneca and Merck & Co (LON:AZN), Inc., Kenilworth, N.J., US today announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets. Women with BRCA-mutated..